Stockscreener 앱 받기
84.46
1.20%
-1.03
시간 외 거래:
84.48
0.02
+0.02%
전일 마감가:
$85.49
열려 있는:
$86.49
하루 거래량:
499.69K
Relative Volume:
0.46
시가총액:
$5.59B
수익:
-
순이익/손실:
$-116.25M
주가수익비율:
-35.32
EPS:
-2.3912
순현금흐름:
$-91.19M
1주 성능:
-11.06%
1개월 성능:
-17.05%
6개월 성능:
+92.79%
1년 성능:
+461.20%
1일 변동 폭
$84.00
$86.49
1주일 범위
$82.69
$96.78
52주 변동 폭
$15.00
$115.52
Oruka Therapeutics Inc Stock (ORKA) Company Profile
명칭
Oruka Therapeutics Inc
전화
650-606-7910
주소
855 OAK GROVE AVE., MENLO PARK
Compare ORKA vs VRTX, REGN, MRNA, ARGX, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ORKA
Oruka Therapeutics Inc
|
84.46 | 5.59B | 0 | -116.25M | -91.19M | -2.3912 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Oruka Therapeutics Inc Stock (ORKA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-18 | 개시 | Piper Sandler | Overweight |
| 2025-11-13 | 개시 | Jefferies | Buy |
| 2025-10-27 | 개시 | Guggenheim | Buy |
| 2025-10-13 | 개시 | Barclays | Overweight |
| 2025-05-22 | 개시 | BTIG Research | Buy |
| 2025-02-04 | 개시 | Wolfe Research | Outperform |
| 2024-10-11 | 개시 | Stifel | Buy |
| 2024-10-07 | 개시 | H.C. Wainwright | Buy |
| 2024-09-17 | 개시 | Leerink Partners | Outperform |
| 2024-09-16 | 개시 | TD Cowen | Buy |
| 2024-09-13 | 개시 | Jefferies | Buy |
| 2018-02-27 | 개시 | Ascendiant Capital Markets | Buy |
| 2013-10-09 | 개시 | Dawson James | Buy |
모두보기
Oruka Therapeutics Inc 주식(ORKA)의 최신 뉴스
Oruka Therapeutics, Inc. (ORKA) stock price, news, quote and history - Yahoo Finance UK
Oruka Therapeutics' Psoriasis Treatment Maintains 'Competitive Profile' After Positive Clinical Data, UBS Says - finance.yahoo.com
Oruka Therapeutics, Inc. (ORKA) Stock Price, News, Quote & History - Yahoo! Finance Canada
ORKA Stock Down 5% Despite Positive Week 28 Psoriasis Efficacy Data - finance.yahoo.com
Oruka Therapeutics stock price target maintained at $120 by H.C. Wainwright - Investing.com Canada
Oruka Therapeutics stock falls despite positive trial data - Investing.com
Clear Street Maintains Oruka Therapeutics(ORKA.US) With Buy Rating, Maintains Target Price $131 - Moomoo
What Oruka Therapeutics (ORKA)'s Phase 2a Psoriasis Data Means For Shareholders - finance.yahoo.com
ORKA Stock Is Soaring After Psoriasis Trial Results — Here's Why BTIG Hiked Its Price Target By 94% - Stocktwits
Oruka Shares Fall Despite Deepening Week 28 Responses for ORKA-001 - marketscreener.com
Update: Oruka Shares Fall Despite Deepening Week 28 Responses for ORKA-001 - finance.yahoo.com
10 Health Care Stocks Whale Activity In Today’s Session - Benzinga
Oruka posts trial data for plaque psoriasis drug (ORKA:NASDAQ) - Seeking Alpha
Oruka Therapeutics Says Psoriasis Drug Shows Deepening Efficacy - AOL.com
Why is Oruka Therapeutics stock sliding today? By Investing.com - Investing.com Canada
Oruka Therapeutics Reports Deepening Responses for ORKA-001 Through Week 28 - marketscreener.com
Oruka Therapeutics Shares Fall 5% After Week 28 ORKA-001 Trial Data - Yahoo Finance
Oruka Therapeutics stock falls despite positive trial data By Investing.com - Investing.com Australia
Oruka reports week 28 psoriasis trial results for ORKA-001 By Investing.com - Investing.com Canada
In a psoriasis trial, 71% had clear skin six months after their last dose - Stock Titan
Oruka Therapeutics general counsel Paul Quinlan sells $936k in stock - Investing.com Nigeria
Form 4 Oruka Therapeutics Inc For: 22 September By Investing.com - Investing.com Canada
Form 4 Oruka Therapeutics Inc For: 22 September - Investing.com UK
Details on Warrant Exercise and Subsequent Share Sales by Oruka Therapeutics' General Counsel - Kalkine Media
Oruka Therapeutics SVP Arjun Agarwal Sells 533 Shares Under Rule 10b5-1 Plan - Kalkine Media
Oruka Therapeutics SVP Arjun Agarwal sells $51,034 in ORKA stock By Investing.com - Investing.com South Africa
Oruka Therapeutics SVP Arjun Agarwal sells $51,034 in ORKA stock - Investing.com UK
Oruka Therapeutics Insider Sold Shares Worth $936,417, According to a Recent SEC Filing - marketscreener.com
Oruka Therapeutics (NASDAQ: ORKA) insider plans new share sale after recent 10b5-1 trades - Stock Titan
Oruka Therapeutics, Inc. (ORKA) Stock Analysis: A 58.6% Potential Upside Beckons Biotech Investors - DirectorsTalk Interviews
LifeSci Capital Maintains Oruka Therapeutics(ORKA.US) With Buy Rating, Maintains Target Price $175 - Moomoo
Halozyme Therapeutics, Inc. Announces Pricing of Upsized Private Offering of $1.3 Billion of Convertible Senior Notes due 2033 - PR Newswire
Oruka Therapeutics COO Sandler sells $86,713 in common stock By Investing.com - Investing.com South Africa
Oruka Therapeutics chief medical officer Joana Goncalves sells $734k in shares By Investing.com - Investing.com South Africa
Oruka Therapeutics SVP Agarwal sells over $926k in common stock By Investing.com - Investing.com South Africa
Oruka Therapeutics SVP Agarwal sells over $926k in common stock - Investing.com Canada
Oruka Therapeutics CEO Lawrence Klein sells $234,680 in ORKA stock - Investing.com
Oruka Therapeutics chief medical officer Joana Goncalves sells $734k in shares - Investing.com UK
Oruka Therapeutics general counsel Paul Quinlan sells $99,442 in stock - Investing.com UK
Oruka Therapeutics COO Sandler sells $86,713 in common stock - Investing.com
Oruka Therapeutics CEO Lawrence Klein Executes 2,452-Share Sale for RSU Tax Withholding - Kalkine Media
Oruka Therapeutics SVP Finance Arjun Agarwal Reports Multiple Stock Option Exercises and Sales - Kalkine Media
Oruka Therapeutics to Attend Morgan Stanley Global Healthcare Conference - Bitget
Morgan Stanley's New York healthcare conference includes Oruka - Stock Titan
Oruka Therapeutics to Attend the 2026 Morgan Stanley Global Healthcare Conference - GlobeNewswire
About Oruka Therapeutics Inc aStock - Coinbase
ORKA News | ORUKA THERAPEUTICS INC (NASDAQ:ORKA) - ChartMill
H.C. Wainwright reiterates Oruka Therapeutics stock rating at buy By Investing.com - Investing.com Canada
H.C. Wainwright reiterates Oruka Therapeutics stock rating at buy - Investing.com UK
UBS Maintains Oruka Therapeutics(ORKA.US) With Buy Rating, Maintains Target Price $130 - Moomoo
Oruka Therapeutics CEO Klein sells $6.8m in stock By Investing.com - Investing.com South Africa
Oruka Therapeutics Inc (ORKA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.06%
2.55%
자본화:
|
볼륨(24시간):